In-vitro activity of twelve antibacterial agents against Neisseria gonorrhoeae.
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D004357:Drug Synergism; D004917:Erythromycin / Q000494:pharmacology; D005493:Folic Acid Antagonists / Q000494:pharmacology; D005839:Gentamicins / Q000494:pharmacology; D007612:Kanamycin / Q000494:pharmacology; D008034:Lincomycin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D013307:Streptomycin / Q000494:pharmacology; D013420:Sulfamethoxazole / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D005493:Folic Acid Antagonists; D005839:Gentamicins; D010406:Penicillins; D011743:Pyrimidines; D007612:Kanamycin; D004917:Erythromycin; D008034:Lincomycin; D013752:Tetracycline; D013420:Sulfamethoxazole; D012293:Rifampin; D013307:Streptomycin